argenx_logo_default.png
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023 01:00 ET | argenx SE
January 27, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023 13:30 ET | argenx SE
January 16, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx_logo_default.png
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 09, 2023 01:00 ET | argenx SE
Reported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130...
argenx_logo_default.png
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 01:00 ET | argenx SE
January 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022 16:01 ET | argenx SE
December 12, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx_logo_default.png
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
December 10, 2022 11:30 ET | argenx SE
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease VYVGART showed rapid, clinically and...
argenx_logo_default.png
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 30, 2022 01:00 ET | argenx SE
Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx_logo_default.png
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 22, 2022 01:00 ET | argenx SE
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at...
argenx_logo_default.png
argenx to Present at Upcoming Investor Conferences
November 07, 2022 01:00 ET | argenx SE
November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022 01:00 ET | argenx SE
$131 million in third quarter VYVGART® (efgartigimod alfa-fcab) global net product sales Filed Biologics License Application (BLA) for subcutaneous (SC) efgartigimod for treatment of generalized...